Just caught that Bristol Myers Squibb got FDA approval for Sotyktu to treat psoriatic arthritis. Honestly didn't realize they were expanding it beyond the psoriasis indication - apparently it's the first TYK2 inhibitor approved specifically for psoriatic arthritis, which is kind of a big deal if you're following the immunology space.

The approval was based on those POETYK trials (PsA-1 and PsA-2) where patients on the 6mg daily dose showed solid improvements in disease activity. They're measuring it by ACR20 response and MDA scores - basically the standard metrics for psoriatic arthritis progression. The data apparently looked good enough that multiple countries have already cleared it.

BMY stock had a mild reaction when this news hit - moved a bit but nothing dramatic. They've got five years of clinical data on this drug now between the psoriasis indication and everything else, so there's decent confidence behind it. Interesting to see how psoriatic arthritis treatment evolves with these newer targeted approaches instead of the heavier immunosuppressants.